You are here

Clinical Trials: Liver Disease

Each Clinical Trial will open in a new browser window or tab.

Return to Clinical Trials Page

Posted: Friday, August 19, 2022 - 12:00
Condition:   Cirrhosis Due to Hepatitis B
Interventions:   Biological: UC-MSCs;   Biological: Saline solution
Sponsors:   Renmin Hospital of Wuhan University;   VCANBIO Cell & Gene Engineering Corporation, Ltd;   Wuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd., Hubei, China
Posted: Monday, August 8, 2022 - 12:00
Condition:   Acute Liver Failure
Intervention:   Biological: HMB002
Sponsors:   King's College Hospital NHS Trust;   Medical Research Council
Not yet recruiting
Posted: Tuesday, March 30, 2021 - 12:00
Condition:   Acute-On-Chronic Liver Failure
Intervention:   Genetic: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)
Sponsor:   Hai Li
Not yet recruiting
Posted: Friday, February 19, 2021 - 12:00
Condition:   Fatty Liver, Nonalcoholic
Interventions:   Drug: Cilostazol 50 MG;   Drug: Placebo
Sponsor:   Sadat City University
Posted: Wednesday, February 17, 2021 - 12:00
Condition:   Patients Having a Scheduled Abdominal Surgery Procedure
Interventions:   Other: blood samples;   Other: biopsy of abdominal paroie
Sponsor:   Assistance Publique - Hôpitaux de Paris
Not yet recruiting
Posted: Wednesday, April 22, 2020 - 12:00
Condition:   Liver Cirrhoses
Intervention:   Biological: Allogeneic Umbilical Cord Mesenchymal Stem Cell
Sponsor:   PT. Prodia Stem Cell Indonesia
Posted: Tuesday, January 28, 2020 - 12:00
Condition:   Cirrhosis, Liver
Interventions:   Combination Product: CD 34 and MSC infusion;   Drug: Standard of care for Cirrhosis management
Sponsor:   Asian Institute of Gastroenterology, India
Posted: Thursday, September 12, 2019 - 12:00
Condition:   Liver Cirrhosis
Intervention:   Drug: GXHPC1
Sponsor:   Gwo Xi Stem Cell Applied Technology Co., Ltd.
Not yet recruiting
Posted: Monday, May 27, 2019 - 12:00
Condition:   NASH - Nonalcoholic Steatohepatitis
Intervention:   Drug: HepaStem
Sponsor:   Promethera Biosciences
Posted: Tuesday, May 21, 2019 - 12:00
Condition:   Liver Cirrhosis
Interventions:   Biological: 2 times SHED group;   Biological: 4 times SHED group
Sponsors:   Changhai Hospital;   Eastern Hepatobiliary Surgery Hospital;   CAR-T (Shanghai) Biotechnology Co., Ltd.
Not yet recruiting